Oseltamivir activity against avian influenza H9N2 strain with different point mutations in their neuraminidase
| dc.contributor.author | Kumosani, Taha Abdullah | |
| dc.contributor.author | Ahmadieh, Diana M. | |
| dc.contributor.author | Shaib, Houssam A. | |
| dc.contributor.author | Hamadeh, Shadi K. | |
| dc.contributor.author | Jaber, Lina S. | |
| dc.contributor.author | Harakeh, Steve Mustapha | |
| dc.contributor.author | Iyer, Archana P. | |
| dc.contributor.author | Azhar, Esam Ibraheem | |
| dc.contributor.author | Barbour, Elie K. | |
| dc.contributor.department | Department of Agriculture | |
| dc.contributor.faculty | Faculty of Agricultural and Food Sciences (FAFS) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:18:04Z | |
| dc.date.available | 2025-01-24T12:18:04Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | The present study has two aims: to optimize the antiviral activity of oseltamivir in chicken embryos against an avian influenza-H9N2 strain (P0) and to apply the optimized protocol for studying the drug susceptibility of 4 H9N2 mutants (M1, M2, M3, and M4). As for the first aim, oseltamivir antiviral activity was monitored upon its delivery into 9-day-old chicken embryo at a concentration of 0.27 mg/100 μl, against 7 doses of the P0 strain, ranging between 1.2 × 10-5 and 2.0 Hemagglutination (HA) units. Oseltamivir showed its highest efficacy in reduction of viral propagation (95% reduction in HA titer) (P < 0.05), when the inoculum level contained a minimum HA units of 1.2 × 10-5. For the second aim of this study, the application of the 1.2 × 10-5 HA units of the virus in inocula for the evaluation of oseltamivir‑antiviral effect against the 4 H9N2 mutants revealed an emergence of a resistant mutant (M1), associated with 2 adjacent point mutations in its neuraminidase (N) amino acid (aa) sequence at positions 46 and 47. The other 3 mutants maintained a variable sensitivity to oseltamivir, resulting in the following reduction in HA titers: M2 (82.9%), M3 (61.5%), and M4 (100.0%). How the point mutations of the neuraminidase sequences affected the susceptibility of H9N2 virus to oseltamivir is still to be determined and deserve further investigations. © 2015, Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise “G.Caporale”. All rights reserved. | |
| dc.identifier.doi | https://doi.org/10.12834/VetIt.013.05.256 | |
| dc.identifier.uri | http://hdl.handle.net/10938/33890 | |
| dc.language.iso | en | |
| dc.publisher | Istituto Zooprofilattico dell'Abruzzo e del Molise | |
| dc.source | Scopus | |
| dc.subject | Avian influenza | |
| dc.subject | Embryonic growth | |
| dc.subject | H9n2 | |
| dc.subject | Mutants | |
| dc.subject | Neuraminidase | |
| dc.subject | Oseltamivir | |
| dc.subject | Animals | |
| dc.subject | Antiviral agents | |
| dc.subject | Birds | |
| dc.subject | Chick embryo | |
| dc.subject | Influenza a virus, h9n2 subtype | |
| dc.subject | Influenza in birds | |
| dc.subject | Point mutation | |
| dc.subject | Antivirus agent | |
| dc.subject | Sialidase | |
| dc.subject | Animal | |
| dc.subject | Bird | |
| dc.subject | Drug effects | |
| dc.subject | Enzymology | |
| dc.subject | Genetics | |
| dc.subject | Influenza a virus (h9n2) | |
| dc.title | Oseltamivir activity against avian influenza H9N2 strain with different point mutations in their neuraminidase | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1